BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today presented new preclinical data from its gene therapy program at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress from October 22-25, 2019 in Barcelona, Spain.

COPAN continues to innovate and is leading the field of Artificial Intelligence (A.I.) and digital culture plate reading in clinical Microbiology.

Dr. Reddy’s Laboratories Ltd. confirms it had initiated a voluntary nationwide recall on October 1, 2019, of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine above levels established by the FDA.

Eli Lilly and Company announced that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company.

Viz.ai, the developer of the first synchronized healthcare software using artificial intelligence, announced a $50 million Series B funding.

BrainStorm Cell Therapeutics Inc. will be participating and presenting scientific data at the upcoming Neuromuscular Drug Development Summit, from October 23-25th, in Boston MA. The Summit is dedicated to solving the challenges in developing second generation neuromuscular therapeutics..

Award is one of the highest honors in the category of field service, recognizing commitment to outstanding innovation, leadership and excellence

$4.5 million research collaboration will combine geriatrics, emergency medicine, telehealth to benefit Northern New England seniors

IsoPlexis, the leading life sciences company in the single-cell proteomics space, announced today that it has received $2 million in grant funding from the National Cancer Institute’s Small Business Innovation Research (NCI SBIR) Development Center for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses.

Cheetah Medical, a medical device leader in non-invasive fluid management technology, today delivered a presentation at the American College of Chest Physicians’ Annual Meeting in New Orleans, Louisiana, showing that hospitals with the highest use of Cheetah Medical’s Starling SV™ exhibited the greatest levels of compliance with The Center for Medicare and Medicaid Services sepsis (SEP-1) measures.